MIRAGE Study: Clinical Outcomes of the Mamba Sirolimus-Eluting PTCA Balloon

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 360 participants.

Also called NCT07326735

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 360 participants (enrolled count) (from the registry)
Sponsor
Frisch Medical Device Private Limited (from the registry)
Registry
  • NCT NCT07326735
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Myanmar (Burma), Malaysia (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT07326735. Allocation not applicable; no masking; primary purpose treatment. Start 2023-01-11 (actual); primary completion 2024-01-22 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
MIRAGE Study: Clinical Outcomes of the Mamba Sirolimus-Eluting PTCA Balloon
Condition
Coronary Artery Disease (CAD (coronary artery disease)) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD))
Intervention (Device)
Mamba Sirolimus-Eluting PTCA Balloon
Intervention (Device)
Percutaneous Coronary Angioplasty with Sirolimus-Coated Balloon
Lead sponsor
Frisch Medical Device Private Limited (class: industry)

Record details

Record id
cardio:ct-nct07326735
Content hash
bd6bff2c371c465177a3e9543a3fbdf23d89aec382d9a94f523dbc472fffa1a8